References

Crohn’s disease

10.1016/s0140-6736(16)31711-1 · 2017 · External reference

STRIDE-II: an update on the Selecting Therapeutic Targets in Inflammatory Bowel Disease (STRIDE) initiative of the International Organization for the Study of IBD (IOIBD): determining therapeutic goals for treat-to-target strategies in IBD

10.1053/j.gastro.2020.12.031 · 2021 · External reference

Complications of diagnostic colonoscopy, upper endoscopy, and enteroscopy

10.1016/j.bpg.2016.09.005 · 2016 · External reference

Small bowel healing detected by endoscopy in patients with Crohn’s disease after treatment with antibodies against tumor necrosis factor

10.1016/j.cgh.2019.08.024 · 2020 · External reference

Effect of tight control management on Crohn’s disease (CALM): a multicentre, randomised, controlled phase 3 trial

10.1016/s0140-6736(17)32641-7 · 2017 · External reference

Fecal calprotectin in gastrointestinal disease

10.1093/clinchem/hvad051 · 2023 · External reference

Association between level of fecal calprotectin and progression of Crohn’s disease

10.1016/j.cgh.2019.02.017 · 2019 · External reference

Prediction of disease activity of Crohn’s disease through fecal calprotectin evaluated by balloon-assisted endoscopy

10.1111/jgh.14310 · 2018 · External reference

Does fecal calprotectin equally and accurately measure disease activity in small bowel and large bowel Crohn’s disease? A systematic review

10.5217/ir.2018.00114 · 2019 · External reference

Correlation of faecal calprotectin and lactoferrin with an endoscopic score for Crohn’s disease and histological findings

10.1111/j.1365-2036.2008.03835.x · 2008 · External reference

A new rapid test for fecal calprotectin predicts endoscopic remission and postoperative recurrence in Crohn’s disease

10.1016/j.crohns.2013.05.005 · 2013 · External reference

Is faecal calprotectin equally useful in all Crohn’s disease locations? a prospective, comparative study

10.5114/aoms.2014.43672 · 2015 · External reference

Variability of faecal calprotectin in inflammatory bowel disease patients: an observational case-control Study

10.1093/ecco-jcc/jjz069 · 2019 · External reference

Diagnostic accuracy of fecal calprotectin in discriminating organic-inflammatory gastrointestinal diseases and functional gastrointestinal disorders in older patients

10.3390/jpm14030227 · 2024 · External reference

Fecal calprotectin

10.1016/bs.acc.2018.07.005 · 2018 · External reference

Compliance with the faecal calprotectin test in patients with inflammatory bowel disease

10.1177/2050640616686517 · 2017 · External reference

Leucine-rich alpha-2 glycoprotein is a serum biomarker of mucosal healing in ulcerative colitis

10.1093/ecco-jcc/jjw132 · 2017 · External reference

Serum leucine-rich α2 glycoprotein: a novel biomarker for small bowel mucosal activity in Crohn’s disease

10.1016/j.cgh.2021.06.036 · 2022 · External reference

LRG1: an emerging player in disease pathogenesis

10.1186/s12929-022-00790-6 · 2022 · External reference

Serum leucine-rich alpha-2 glycoprotein as a predictive factor of endoscopic remission in Crohn’s disease

10.1111/jgh.15907 · 2022 · External reference

Combination of leucine-rich alpha-2 glycoprotein and fecal markers detect Crohn’s disease activity confirmed by balloon-assisted enteroscopy

10.5217/ir.2023.00092 · 2024 · External reference

Proton pump inhibitor use is associated with elevated faecal calprotectin levels. A cross-sectional study on subjects referred for colonoscopy

10.1080/00365521.2019.1566493 · 2019 · External reference

Prescription of NSAIDs and proton pump inhibitors are associated with increased faecal calprotectin levels in patients with functional bowel disorder: an observational study

10.1080/00365521.2025.2512368 · 2025 · External reference

A review on the current status and definitions of activity indices in inflammatory bowel disease: how to use indices for precise evaluation

10.1007/s00535-022-01862-y · 2022 · External reference

Utility of magnetic resonance enterography for small bowel endoscopic healing in patients with Crohn’s disease

10.1038/ajg.2017.464 · 2018 · External reference

Development and validation of a new, simplified endoscopic activity score for Crohn’s disease: the SES-CD

10.1016/s0016-5107(04)01878-4 · 2004 · External reference

Serum ficolin-2 correlates worse than fecal calprotectin and CRP with endoscopic Crohn’s disease activity

10.1016/j.crohns.2014.02.014 · 2014 · External reference

A systematic review of measurement of endoscopic disease activity and mucosal healing in Crohn’s disease: recommendations for clinical trial design

10.1097/mib.0000000000000131 · 2014 · External reference

IOIBD technical review on endoscopic indices for Crohn’s disease clinical trials

10.1136/gutjnl-2015-309903 · 2016 · External reference

Accuracy of serum leucine-rich alpha-2 glycoprotein in evaluating endoscopic disease activity in Crohn’s disease

10.1093/ibd/izac076 · 2023 · External reference

Fecal calprotectin correlates more closely with the Simple Endoscopic Score for Crohn’s disease (SES-CD) than CRP, blood leukocytes, and the CDAI

10.1038/ajg.2009.545 · 2010 · External reference

Significance of endoscopic deep small bowel evaluation using balloon-assisted enteroscopy for Crohn’s disease in clinical remission

10.1007/s00535-020-01737-0 · 2021 · External reference

Diagnostic accuracy and cut-off values of serum leucine-rich alpha-2 glycoprotein for Crohn’s disease activity in the small bowel

10.1007/s00535-025-02223-1 · 2025 · External reference

Leucine-rich alpha-2 glycoprotein as a marker of mucosal healing in inflammatory bowel disease

10.1038/s41598-021-90441-x · 2021 · External reference

Leucine-rich alpha-2 glycoprotein is a potential biomarker to monitor disease activity in inflammatory bowel disease receiving adalimumab: PLANET study

10.1007/s00535-021-01793-0 · 2021 · External reference

The role of calprotectin in the diagnosis and treatment of inflammatory bowel disease

10.3390/ijms26051996 · 2025 · External reference

Clinical profiles of leucine-rich alpha-2 glycoprotein for indicating mucosal healing in ulcerative colitis patients under administration of molecular-targeted drug

10.1159/000542062 · 2025 · External reference

Fecal calprotectin in patients with Crohn’s disease: a study based on the history of bowel resection and location of disease

10.3390/diagnostics14080854 · 2024 · External reference